

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

<i>Product:</i>	Curam
<i>Active Ingredients:</i>	Amoxicillin sodium 1.06g equivalent to amoxicillin 1g Potassium clavulanate 238.3mg equivalent to clavulanic acid 200mg
<i>Dosage Form:</i>	Powder for injection
<i>New Zealand Sponsor:</i>	Novartis New Zealand Limited
<i>Manufacturer:</i>	Reig Jofre SA, Toledo, Spain
<i>Product:</i>	Curam
<i>Active Ingredients:</i>	Amoxicillin sodium 530mg equivalent to amoxicillin 500mg Potassium clavulanate 119.15mg equivalent to clavulanic acid 100mg
<i>Dosage Form:</i>	Powder for injection
<i>New Zealand Sponsor:</i>	Novartis New Zealand Limited
<i>Manufacturer:</i>	Reig Jofre SA, Toledo, Spain
<i>Product:</i>	Eltroxin
<i>Active Ingredient:</i>	Levothyroxine sodium 111.26µg equivalent to thyroxine sodium 100µg
<i>Dosage Form:</i>	Tablet
<i>New Zealand Sponsor:</i>	GlaxoSmithKline (NZ) Limited
<i>Manufacturer:</i>	Glaxo Wellcome GmbH & Co, Bad Oldesloe, Germany
<i>Product:</i>	Eltroxin
<i>Active Ingredient:</i>	Levothyroxine sodium 55.63µg equivalent to thyroxine sodium 50µg
<i>Dosage Form:</i>	Tablet
<i>New Zealand Sponsor:</i>	GlaxoSmithKline (NZ) Limited
<i>Manufacturer:</i>	Glaxo Wellcome GmbH & Co, Bad Oldesloe, Germany
<i>Product:</i>	Fosamax Plus
<i>Active Ingredients:</i>	Alendronate sodium 91.37mg equivalent to 70mg anhydrous free acid Colecalciferol 70µg
<i>Dosage Form:</i>	Tablet
<i>New Zealand Sponsor:</i>	Merck Sharp & Dohme (New Zealand) Limited
<i>Manufacturer:</i>	MSD Frosst Iberica SA, Alcala de Henares, Madrid, Spain
<i>Product:</i>	Hydrogen Peroxide Neutralising Tablets
<i>Active Ingredient:</i>	Catalase 0.1mg
<i>Dosage Form:</i>	Tablet for contact lens solution
<i>New Zealand Sponsor:</i>	Advanced Medical Optics Australia Pty Limited
<i>Manufacturer:</i>	Nicholas Piramal India Limited, Parel, Mumbai, India
<i>Product:</i>	Norspan
<i>Active Ingredient:</i>	Buprenorphine 10mg
<i>Dosage Form:</i>	Transdermal patch
<i>New Zealand Sponsor:</i>	Mundipharma New Zealand Limited
<i>Manufacturer:</i>	LTS Lohmann Therapie-Systeme AG, Andernach, Germany
<i>Product:</i>	Norspan
<i>Active Ingredient:</i>	Buprenorphine 20mg
<i>Dosage Form:</i>	Transdermal patch
<i>New Zealand Sponsor:</i>	Mundipharma New Zealand Limited
<i>Manufacturer:</i>	LTS Lohmann Therapie-Systeme AG, Andernach, Germany
<i>Product:</i>	Norspan
<i>Active Ingredient:</i>	Buprenorphine 5mg
<i>Dosage Form:</i>	Transdermal patch
<i>New Zealand Sponsor:</i>	Mundipharma New Zealand Limited
<i>Manufacturer:</i>	LTS Lohmann Therapie-Systeme AG, Andernach, Germany
<i>Product:</i>	Octanate
<i>Active Ingredient:</i>	Factor VIII, human 1,000IU
<i>Dosage Form:</i>	Powder for injection

New Zealand Sponsor: Diluent
Octapharma New Zealand Limited
Manufacturers: Octapharma Pharmazeutika Produktionsges, Vienna, Austria
Octapharma, Lingolsheim, France

Product: **Octanate**
Active Ingredient: Factor VIII, human 250IU
Dosage Form: Powder for injection

Diluent
New Zealand Sponsor: Octapharma New Zealand Limited
Manufacturers: Octapharma Pharmazeutika Produktionsges, Vienna, Austria
Octapharma, Lingolsheim, France

Product: **Octanate**
Active Ingredient: Factor VIII, human 500IU
Dosage Form: Powder for injection

Diluent
New Zealand Sponsor: Octapharma New Zealand Limited
Manufacturers: Octapharma Pharmazeutika Produktionsges, Vienna, Austria
Octapharma, Lingolsheim, France

Dated this 10th day of November 2006.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go7945
